

# ORAL CANCER PREVENTION

VOLUME 19

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met remotely, 4–11 December 2021

LYON, FRANCE - 2023

IARC HANDBOOKS OF  
CANCER PREVENTION

# LIST OF PARTICIPANTS

---

## Members <sup>1</sup>

*Devasena Anantharaman*

Rajiv Gandhi Centre for Biotechnology  
Thiruvananthapuram

*Olalekan A. Ayo-Yusuf (Subgroup Chair,  
Interventions for Cessation)*

Sefako Makgatho Health Sciences University  
and  
School of Health Systems and Public Health  
University of Pretoria  
Pretoria

*Anil Chaturvedi <sup>2</sup> (Subgroup Co-Chair,  
Impact of Cessation)*

Division of Cancer Epidemiology and  
Genetics  
National Cancer Institute  
National Institutes of Health  
Bethesda

*Tony Hsiu-Hsi Chen (Subgroup Co-Chair,  
Impact of Cessation)*

Institute of Epidemiology and Preventive  
Medicine  
NTU  
Taipei

---

<sup>1</sup> Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only. Invited Specialists do not serve as Meeting Chair or Subgroup Chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. Each participant was asked to declare potentially relevant research, employment, and financial interests that are current or that have occurred during the past 4 years. Minimal interests are not disclosed here and include stock valued at no more than US\$ 1000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All other non-publicly funded grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are disclosed as potentially significant conflicts of interests.

<sup>2</sup> Anil Chaturvedi reports that his unit at NCI/NIH benefits from VELscope equipment for oral cancer screening from LED Dental Ltd.

*David I. Conway*

School of Medicine, Dentistry, and Nursing  
University of Glasgow  
Glasgow

*Prakash C. Gupta*

Healis Sekhsaria Institute for Public Health  
Navi Mumbai

*Newell W. Johnson*

Griffith University  
Gold Coast  
and  
Faculty of Dentistry, Oral, and Craniofacial  
Sciences  
King's College London  
London

*Alexander Ross Kerr (Subgroup Chair,  
Screening)*

New York University College of Dentistry  
New York

*Luiz P. Kowalski*

University of São Paulo Medical School  
and  
A.C. Camargo Cancer Center  
São Paulo

*Maria Elena Leon*

Retired  
Panama City

*Olena Mandrik*

The University of Sheffield School of Health  
and Related Research  
Sheffield

*Ravi Mehrotra (Meeting Co-Chair)*

Centre for Health Innovation and Policy  
Foundation  
Noida  
and  
Rollins School of Public Health  
Emory University  
Atlanta

*Toru Nagao*

Department of Maxillofacial Surgery  
School of Dentistry  
Aichi Gakuin University  
Nagoya

*Vinayak M. Prasad*

World Health Organization  
Geneva

*Kunnambath Ramadas*

Regional Cancer Centre  
Thiruvananthapuram

*Felipe Roitberg*

World Health Organization  
Geneva

*Pierre Saintigny*

Univ Lyon, Université Claude Bernard  
Lyon 1, INSERM 1052, CNRS 5286,  
Centre Léon Bérard, Centre de recherche  
en cancérologie de Lyon  
and  
Department of Medical Oncology,  
Centre Léon Bérard  
Lyon

***Alan Roger Santos-Silva***

Piracicaba Dental School  
University of Campinas  
Piracicaba, São Paulo

***Dhirendra Narain Sinha***

School of Preventive Oncology  
Patna

***Wanninayake M. Tilakaratne***

University of Peradeniya  
Peradeniya  
and  
Faculty of Dentistry, University of Malaya  
Kuala Lumpur

***Patravoot Vatanasapt***

Department of Otorhinolaryngology  
Faculty of Medicine  
Khon Kaen University  
Khon Kaen

***Saman Warnakulasuriya (Meeting Co-Chair)***

King's College London  
WHO Collaborating Centre for Oral Cancer  
London

***Rosnah B. Zain***

MAHSA University  
Selangor  
and  
Faculty of Dentistry, University of Malaya  
Kuala Lumpur

**Invited Specialists*****Ann Gillenwater*<sup>3</sup> (unable to attend)**

UT MD Anderson Cancer Center  
Houston

***Rengaswamy Sankaranarayanan*<sup>4</sup>**

Preventive Oncology  
Karkinos Healthcare Pvt Ltd  
Coimbatore  
and  
International Agency for Research on Cancer  
Lyon

**Representatives*****Frédéric de Bels***

French National Cancer Institute  
Boulogne-Billancourt

***Luciana Neamtiu***

European Commission  
Ispra

***Carolina Wiesner***

Colombian National Cancer Institute  
Bogotá

<sup>3</sup> Ann Gillenwater reports receiving personal consultancy fees from Rakuten Medical, that her unit at the University of Texas benefits from research funding from NRG Oncology, and holding United States Patents no. 7365844 B2 and no. 7499161 B2.

<sup>4</sup> Rengaswamy Sankaranarayanan reports being a salaried advisor for Karkinos Healthcare Pvt Ltd.

**Observers**<sup>5</sup>*Pankaj Chaturvedi*

Tata Memorial Centre  
Department of Atomic Energy, Government  
of India  
Mumbai

*Moni Abraham Kuriakose*

Roswell Park Comprehensive Cancer Center  
Buffalo

*Andrey Moreno Torres*

Colombian National Cancer Institute  
Bogotá

Rok Ho Kim, WHO headquarters  
Béatrice Lauby-Secretan, Head of the *IARC Handbooks* Programme, Deputy Head of the Evidence Synthesis and Classification Branch

Filip Meheus, Cancer Surveillance Branch  
Karen Müller, Services to Science and Research Branch (*Editor*)

Richard Muwonge, Early Detection, Prevention, and Infections Branch  
Suzanne Nethan, Evidence Synthesis and Classification Branch (*Rapporteur*)

Sandra Perdomo, Genomic Epidemiology Branch

Deependra Singh, Cancer Surveillance Branch (*Rapporteur*)

Maria Pura Solon, WHO headquarters  
Benoît Varenne, WHO headquarters  
Shama Virani, Genomic Epidemiology Branch

**IARC/WHO Secretariat**

Véronique Bouvard, Evidence Synthesis and Classification Branch (*Responsible Officer, Rapporteur*)

Andre Carvalho, Early Detection, Prevention, and Infections Branch  
Chrysovalantou Chatziioannou, Nutrition and Metabolism Branch

Ana Carolina de Carvalho, Genomic Epidemiology Branch

Gampo Dorji, WHO Regional Office for South-East Asia

Thushara Eraj Indranath Fernando, WHO Regional Office for South-East Asia

Andre Ilbawi, WHO headquarters

Jagdish Kaur, WHO Regional Office for South-East Asia

**Administrative Assistance**

Marieke Dusenbergh

**Production Team**

Niree Kraushaar  
Solène Quennehen

**Scientific Assistance**

Irena Duś-Ilnicka  
Ana Carolina de Carvalho, IARC  
Chrysovalantou Chatziioannou, IARC

<sup>5</sup> Each Observer agreed to respect the Guidelines for Observers at *IARC Handbooks* meetings. Observers did not serve as Meeting Chair or Subgroup Chair, draft or revise any part of the *Handbook*, or participate in the evaluations. They also agreed not to contact participants before or after the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.